Summary Text

SUMMARY: First diagnosed with myeloma October 2011. Recruited onto clinical trial Myeloma X11 (Lenalidomide) at Bristol Oncology and Haematology Centre. First High Dose Therapy and Stem Cell Transplant (HDT&SCT) in July 2012. On maintenance until June 2017. June 2018 recruited onto Myeloma XII trial (Ixazomib). December 2018 Second HDT&SCT. On maintenance until February 2020. August 2020 Commenced treatment involving Daratumumab. April 2021 relapsed. June 2021 recruited onto Cartitude 4 clinical trial and infused with CAR-T cells in October 2021. My own immune system is now fighting the cancer . I am exceedingly fortunate.


Sunday, 14 November 2021

Results

Having been discharged from the ward just over 2 weeks ago I can provide something of an update.  

Certainly I remain fairly weak and have needed to attend review clinics twice a week.  Margaret has been fantastic driving me to Bristol as required.  In addition, I've needed platelet infusions on two occasions.  My consultant says this is to be expected.  He also gave me the exceedingly great news that my paraprotein level has reduced significantly, confirming that the CAR-T cells are indeed attacking the myeloma.  I cannot want for more.

Keep safe, keep well

Stephen